Insulin and IGF-1 receptor agonists and antagonists

US7173005B2 · kind B2 · utility

Assignees

• ANTYRA INC. · US
• Novo Nordisk A/S · DK

Inventors

• Renuka Pillutla · Bound Brook Junction, US
• Olga Dedova · Highland Park, US
• Arthur Blume · Annandale, US
• Neil I. Goldstein · Maplewood, US
• Renee Brissette · Clarksburg, US
• Pinger Wang · Piscataway, US
• Hao Liu · Tampa, US
• Ku-chuan Hsiao · Easton, US
• Michael Lennick · Exton, US
• Paul Fletcher · Cheshire, US

Key dates

• Filing date: Sep 24, 2002
• Grant date: Feb 6, 2007
• Expiry date: Feb 16, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/65
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.